FAS expression inversely correlates with PTEN level in prostate cancer and a PI 3-kinase inhibitor synergizes with FAS siRNA to induce apoptosis

Fatty acid synthase (FAS), a key enzyme of the fatty acid biosynthetic pathway, has been shown to be overexpressed in various types of human cancer and is, therefore, considered to be an attractive target for anticancer therapy. However, the exact mechanism of overexpression of the FAS gene in tumor cells is not well understood. In this report, we demonstrate that the expression of the tumor suppressor gene PTEN has a significant inverse correlation with FAS expression in the case of prostate cancer in the clinical setting, and inhibition of the PTEN gene leads to the overexpression of FAS in vitro. We also found that the combination of the expression status of these two genes is a better prognostic marker than either gene alone. Furthermore, our results indicate that the specific inhibition of FAS gene by siRNA leads to apoptosis of prostate tumor cells, and inhibition of PI 3-kinase pathway synergizes with FAS siRNA to enhance tumor cell death. These results provide a strong rationale for exploring the therapeutic use of an inhibitor of the PTEN signaling pathway in conjunction with the FAS siRNA to inhibit prostate tumor growth.

[1]  F. Kuhajda Fatty-acid synthase and human cancer: new perspectives on its role in tumor biology. , 2000, Nutrition.

[2]  A. Nashimoto,et al.  Fatty acid synthase is highly expressed in carcinoma, adenoma and in regenerative epithelium and intestinal metaplasia of the stomach , 2002, Histopathology.

[3]  R. Seeley,et al.  Comparison of central and peripheral administration of C75 on food intake, body weight, and conditioned taste aversion. , 2002, Diabetes.

[4]  P. Nelson,et al.  Prostate-specific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer. , 2003, Cancer cell.

[5]  L. Cantley,et al.  New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[6]  J. Nelson,et al.  Increased fatty acid synthase as a therapeutic target in androgen‐independent prostate cancer progression , 2001, The Prostate.

[7]  P. Morin,et al.  Activation of fatty acid synthesis during neoplastic transformation: role of mitogen-activated protein kinase and phosphatidylinositol 3-kinase. , 2002, Experimental cell research.

[8]  G. Mick,et al.  Inhibitory effects of cerulenin on protein palmitoylation and insulin internalization in rat adipocytes. , 1995, Biochimica et biophysica acta.

[9]  J. Swinnen,et al.  Stimulation of tumor-associated fatty acid synthase expression by growth factor activation of the sterol regulatory element-binding protein pathway , 2000, Oncogene.

[10]  C. Bosman,et al.  Fatty acid synthase expression in melanoma , 2003, Journal of cutaneous pathology.

[11]  J. Nelson,et al.  Increased fatty acid synthase expression and activity during progression of prostate cancer in the TRAMP model , 2003, The Prostate.

[12]  Kanji A. Takahashi,et al.  The anorexigenic fatty acid synthase inhibitor, C75, is a nonspecific neuronal activator. , 2004, Endocrinology.

[13]  E. Malvoisin,et al.  Effect of drugs which inhibit cholesterol synthesis on syncytia formation in vero cells infected with measles virus. , 1990, Biochimica et biophysica acta.

[14]  G. G. Stokes "J." , 1890, The New Yale Book of Quotations.

[15]  P. Visca,et al.  Expression of fatty acid synthase (FAS) as a predictor of recurrence in stage I breast carcinoma patients , 1996, Cancer.

[16]  A W Partin,et al.  OA-519 (fatty acid synthase) as an independent predictor of pathologic state in adenocarcinoma of the prostate. , 1995, Urology.